

RECEIVED

OCT 01 2002


PTO/SB/08B (10-01)

#10

TECH CENTER 1600/0000

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



1

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

| Complete if Known | |
|------------------------|-------------------------------|
| Application Number | 09/891,138 |
| Filing Date | June 25, 2001 |
| First Named Inventor | Lin, Daniel Chi-Hong, et. al. |
| Art Unit | 1646 1647 |
| Examiner Name | Not yet assigned - NICHOLS |
| Attorney Docket Number | 018781-006210US |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|--------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ | Number ⁴ | | | |
| CD | BA | EP | 1 096 009 | A1 05/02/2001 | Pfizer Limited et al. | <input type="checkbox"/> |
| | BB | WO | 00/22131 | A2 04/20/2000 | Dominic P. Behan et al. | <input type="checkbox"/> |
| | BC | WO | 00/31258 | A2 06/02/2000 | Ruoping Chen et al. | <input type="checkbox"/> |
| | BD | WO | 01/25432 | A2 04/12/2001 | Schering Corporation | <input type="checkbox"/> |
| | BE | WO | 01/33221 | A1 05/10/2001 | SmithKline Beecham Corporation et al | <input type="checkbox"/> |
| | BF | WO | 01/46414 | A1 06/28/2001 | Banyu Pharmaceutical CO., LTD. | <input type="checkbox"/> |
| | BG | WO | 01/85793 | A2 11/15/2001 | Pharmacia & Upjohn Company | <input type="checkbox"/> |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CD | BH | STADEL J. et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 18, no. 11, pp. 430-437, (November 1, 1997) | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |

| | | | |
|--------------------|----------------|-----------------|----------|
| Examiner Signature | <i>Atticus</i> | Date Considered | 4/8/2003 |
|--------------------|----------------|-----------------|----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1388300 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

OCT 09 2001

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/891,138 |
| Filing Date | June 25, 2001 |
| First Named Inventor | Lin, Daniel Chi Hong |
| Group Art Unit | 1640 1647 |
| Examiner Name | NICHOLSE |
| Attorney Docket Number | 018781-006210USC |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| CGN | AA | US 5,871,963 | A | Conley, et al. | 02-16-1999 | RECEIVED ENTER 100-2000 |
| CGN | AB | US 5,955,309 | A | Ellis, et al. | 09-21-1999 | RECEIVED ENTER 100-2000 |
| CGN | AC | US 6,063,582 | A | Conley, et al. | 05-16-2000 | RECEIVED ENTER 100-2000 |
| CGN | AD | US 6,204,017 | B1 | Behan, et al. | 03-20-2001 | RECEIVED ENTER 100-2000 |
| CGN | AE | US 6,222,029 | B1 | Edwards, et al. | 04-24-2001 | RECEIVED ENTER 100-2000 |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|--|----------------------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CGN | AF | EPO | WO 96/05302 | A1 | Takeda Chemical Industries, LTD. | 02-22-1996 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AG | EPO | WO 97/24929 | A1 | Human Genome Sciences, Inc. | 07-17-1997 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AH | EPO | WO 99/06552 | A2 | Genset | 02-11-1999 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AI | EPO | WO 00/11166 | A1 | Millennium Pharmaceuticals, Inc. | 03-02-2000 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AJ | EPO | WO 00/22131 | A2 | Behan, et al. | 04-20-2000 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AK | EPO | WO 00/28032 | A2 | Incite Pharmaceuticals, Inc. | 05-18-2000 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AL | EPO | WO 00/61628 | A1 | Human Genome Sciences, Inc. | 10-19-2000 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AM | EPO | WO 01/31014 | A2 | Pharmacia & Upjohn Company | 05-03-2001 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| | AN | EPO | WO 00/31258 | A2 | Arena Pharmaceuticals, Inc. | 06-02-2000 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| CGN | AO | EPO | WO 01/36473 | A2 | Pharmacia & Upjohn Company | 05-25-2001 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |
| CGN | AP | EPO | EP 1090925 | A1 | Pfizer Limited | 04-11-2001 | RECEIVED ENTER 100-2000 | RECEIVED ENTER 100-2000 |

Examiner Signature

G. Nichols

Date Considered

4/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1277930 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

OCT 09 2001
CIPR JC85 H

PATENT TRADEMARK

TECH CENTER 1600

RECEIVED

OCT 12 2001

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 09/891,138 |
| Filing Date | June 25, 2001 |
| First Named Inventor | Lin, Daniel Chi-Hong |
| Group Art Unit | 1640 1647 |
| Examiner Name | NICHOLS |
| Attorney Docket Number | 018781-006210US |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | |
| CGO | AQ | EPO | EP 1096009 | A1 | Pfizer Limited | 05-02-2001 | _____ |
| | AR | EPO | EP 0892051 | A2 | Smithkline Beecham Corporation | 01-20-1999 | _____ |
| | AS | EPO | EP 0892051 | A3 | Smithkline Beecham Corporation | 01-20-1999 | _____ |
| ↓ | AT | JPO | 08-245697 | | Takeda Chemical Industries, LTD. | 09-24-1996 | _____ |
| CGO | AU | JPO | 11032770 | A | Asahi Kasei Kogyo KK | 07-24-1997 | _____ |
| | | | | | | | |
| | | | | | | | |

| | | | |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 4/8/2003 |
|--------------------|-------------------|-----------------|----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

SF 1277930 v1